Literature DB >> 480149

Sequential first-pass elimination of a metabolite derived from a precursor.

K S Pang, J R Gillette.   

Abstract

We examined data from our previous studies in which we not only delivered perfusate containing tracer concentrations of [14C]phenacetin and its metabolite [3H]acetaminophen under constant perfusate flow (10 ml/min/liver) into the rat liver preparation just once, but also recirculated fresh reservoir perfusate containing a tracer dose of [14C]phenacetin through the same rat liver preparation. From the single-pass studies, estimates of fm, the fractional rate of conversion for [14C]phenacetin to form [14C]acetaminophen, and F(M.P), the apparent availability of [14C]acetaminophen, were obtained by determining the concentrations of [14C]acetaminophen in the perfusate before and after incubation with Glusulase. These estimates were fm = 0.871 +/- 0.16 and F(M.P) = 0.43 +/- 0.10. These and the steady-state clearance values of phenacetin (9.1 +/- 0.8 ml/min) and acetaminophen (6.7 +/- 0.7 ml/min) from the single-pass studies were used to predict the concentrations of [14C]acetaminophen in the reservoir perfusate on recirculation of [14C]phenacetin. We found that the sequential first-pass elimination of the metabolite must be considered when the metabolite is highly extracted by the liver. If we had neglected to take this into account, the fractional rate of conversion of a precursor to form a metabolite and the rate of formation of the metabolite would have been underestimated by the factor F(M.P).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 480149     DOI: 10.1007/bf01060018

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  9 in total

1.  Pharmacokinetics of isoniazid and some metabolites in man.

Authors:  H G Boxenbaum; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1976-08

2.  Clearance concepts in pharmacokinetics.

Authors:  M Rowland; L Z Benet; G G Graham
Journal:  J Pharmacokinet Biopharm       Date:  1973-04

3.  Pharmacokinetic model for chlordiazepoxide--HCl in the dog.

Authors:  S A Kaplan; M Lewis; M A Schwartz; E Postma; S Cotler; C W Abruzzo; T L Lee; R E Weinfeld
Journal:  J Pharm Sci       Date:  1970-11       Impact factor: 3.534

4.  Theoretical relationships between area under the curve and route of administration of drugs and their precursors for evaluating sites and pathways of metabolism.

Authors:  K S Pang; J R Gillette
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

5.  Renal contribution to overall metabolism of drugs. II. Biotransformation of salicylic acid to salicyluric acid.

Authors:  S H Wan; S Riegelman
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534

6.  Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.

Authors:  K S Pang; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

7.  Hepatic clearance of drugs. III. Additional experimental evidence supporting the "well-stirred" model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liver in situ preparation.

Authors:  K S Pang; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

8.  Pharmacokinetics of salicylate elimination in man.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1965-07       Impact factor: 3.534

9.  Kinetics of metabolite formation and elimination in the perfused rat liver preparation: differences between the elimination of preformed acetaminophen and acetaminophen formed from phenacetin.

Authors:  K S Pang; J R Gillette
Journal:  J Pharmacol Exp Ther       Date:  1978-10       Impact factor: 4.030

  9 in total
  17 in total

1.  Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates.

Authors:  Huadong Sun; K Sandy Pang
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 2.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

3.  A comparative investigation of hepatic clearance models: predictions of metabolite formation and elimination.

Authors:  M V St-Pierre; P I Lee; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1992-04

4.  Physiological modeling of drug and metabolite: disposition of oxazepam and oxazepam glucuronides in the recirculating perfused mouse liver preparation.

Authors:  M V St-Pierre; D van den Berg; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

5.  Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.

Authors:  Justin D Lutz; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2011-10-18       Impact factor: 3.922

6.  Kinetics and disposition in toxicology. Example: carcinogenic risk estimate for ethylene.

Authors:  H M Bolt; J G Filser
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

7.  Primary, secondary, and tertiary metabolite kinetics.

Authors:  M V St-Pierre; X Xu; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1988-10

8.  An understanding of the role of enzyme localization of the liver on metabolite kinetics: a computer simulation.

Authors:  K S Pang; R N Stillwell
Journal:  J Pharmacokinet Biopharm       Date:  1983-10

9.  Drug metabolite concentration-time profiles: influence of route of drug administration.

Authors:  J B Houston; G Taylor
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

10.  Fractions metabolized in a triangular metabolic system: cinromide and two metabolites in the rhesus monkey.

Authors:  E A Lane; R H Levy
Journal:  J Pharmacokinet Biopharm       Date:  1985-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.